Clinical trial

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

NCT01479179

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AMG 479 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Trastuzumab Normalized identity: trastuzumabView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2012-11-01

PhasePHASE1 / PHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

AMG 479DRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

M.D. Anderson Cancer Centerlead sponsor

Amgencollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01479179 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.